THE INCREASING GLOBAL INCIDENCE OF ULCERATIVE COLITIS; IMPLICATIONS FOR THE ECONOMIC BURDEN OF ULCERATIVE COLITIS

Author(s)

Richardson J1, Nelson L1, Curry A2, Ralston S2
1SIRIUS Market Access, Newcastle upon Tyne, UK, 2SIRIUS Market Access, London, UK

OBJECTIVES : A literature review was conducted to identify reported trends in the worldwide incidence and prevalence of ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), and potential implications for the economic burden of UC.

METHODS : The MEDLINE database was searched to identify studies related to the epidemiology and costs of UC. Publications with English language abstracts from 2010 onwards were considered.

RESULTS : Published time-trend analyses have indicated global increasing incidence of UC between 1950-2010, followed by stabilisation/ reduction of incidence rates between 1990-2016 in Europe and North America. However, the incidence of UC continues to increase in newly industrialised countries, which is considered to be linked to the westernisation of diets and environments. Despite stabilisation of incidence in western countries, prevalence continues to increase. A 2017 review reported that prevalence has exceeded 0.3% of the total population in North America, Australia, and many European countries. A forecast of the global burden of IBD between 2015 and 2025 predicted exponential growth of the number of patients, due to increased rates of diagnosis and low mortality. UC is associated with high cost burden, a 2010 review estimated the total economic burden of UC to be €12.5-€29.1 billion in Europe and $8.1-$14.9 billion in the US. According to this review, hospitalisations are the largest contributor to direct medical costs. However, a recent study indicates that the proportion of anti-TNF (biologics) related costs are increasing. Although the introduction of biosimilars may reduce costs, this may be offset by the increasing number of patients requiring treatment.

CONCLUSIONS : Healthcare systems worldwide should be aware of the increasing prevalence of UC, which may result in increased economic burden. As reported incidence and prevalence rates have recently increased, updated epidemiology studies are required to ensure data used in economic models is up-to-date and region-specific.

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PGI5

Topic

Epidemiology & Public Health

Disease

Gastrointestinal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×